Thanks to this operation, that is subject to the approval of the competition authorities, the Group will reach 1,300 employees in Spain and 3,500 globally, with a consolidated turnover of over 1 billion euros.
As part of the measures to support the development of collaborations for the identification of therapies and diagnostic, protection and analysis systems to combat the Coronavirus emergency and other viral emergencies of the future, the Lombardy Region has financed the project "EPIgenetic Therapy for the treatment of COronavirus infections "- Acronym: EPICO
Ghemaxan is indicated for the treatment of deep vein thrombosis and pulmonary embolism (except for PE which may require thrombolytic or surgical therapy), serious [...]
Italfarmaco committed to its mission to contribute to the improvement of the quality and the prolongation of human lifespan, is proud to support the [...]
Italfarmaco Group announces the acquisition of the remaining 50% of Effik, S.A.